NCT05795595 2025-11-26
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
CRISPR Therapeutics
Phase 1/2 Completed
Clinical Trials
29 trialsNCT05263245 2025-09-03
Skippy 1
Leiden University Medical Center
Phase 2 Completed
NCT01398306 2024-05-06
BANN
University Medical Center Groningen
Completed
NCT05375136 2024-03-25
A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients
Eisai Inc.
Completed
NCT00946881 2024-02-07
Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer
Steba Biotech S.A.
Phase 1/2 Completed
NCT00606866 2023-11-29
MRI
University of Chicago
Phase 3 Completed
NCT03633110 2022-04-19
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
Genocea Biosciences, Inc.
Phase 1/2 Completed
NCT01353625 2021-10-05
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
Celgene
Phase 1 Completed
NCT02793128 2020-12-22
Olympus
UroGen Pharma Ltd.
Phase 3 Completed
NCT00722553 2019-12-17
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
Acrotech Biopharma Inc.
Phase 2 Completed
NCT02300610 2019-08-01
Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01310894 2019-07-11
PCM301
Steba Biotech S.A.
Phase 3 Completed
NCT01529411 2019-04-04
MAJA
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT02454478 2019-03-19
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
Eisai Inc.
Phase 1 Completed
NCT00838201 2018-10-18
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
Amgen
Phase 3 Completed
NCT00529802 2018-04-25
Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer
University of Chicago
Phase 2 Completed
NCT01431391 2017-05-30
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Dendreon
Phase 2 Completed
NCT00719264 2017-03-20
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Novartis
Phase 2 Completed
NCT00035113 2017-02-09
EPO906 Therapy in Patients With Prostate Cancer
Novartis
Phase 2 Completed
NCT00688753 2016-09-02
MACS0460
Novartis
Phase 2 Completed
NCT00707356 2016-04-19
Study of WST11 in Patients With Localized Prostate Cancer
Steba Biotech S.A.
Phase 2 Completed
NCT01135849 2015-11-17
B-Receptor Signaling in Cardiomyopathy
Stanford University
Completed
NCT00842790 2015-10-06
REMISCAN
Assistance Publique - Hôpitaux de Paris
Completed
NCT00975429 2015-04-28
Study Using WST11 in Patients With Localized Prostate Cancer
Steba Biotech S.A.
Phase 2 Completed
NCT00441337 2015-02-20
MDX1106-01
Bristol-Myers Squibb
Phase 1 Completed
NCT00141765 2014-06-20
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00771147 2012-06-15
PONDIAC
Bayer
Completed
NCT00895674 2010-09-30
Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
Bayer
Completed
NCT00343356 2006-06-22
Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder
LanZhou University
Phase 2 Completed